BlossomHill Therapeutics Inc BLSM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
-
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
-
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
-
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
-
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
-
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
Trading Information
- Previous Close Price
- $14.98
- Day Range
- $13.31–14.79
- 52-Week Range
- $13.31–27.99
- Bid/Ask
- $14.21 / $20.98
- Shares Outstanding
- 31.78M
- Market Cap
- $443.08M
- Volume/Avg
- 293,108 / 249,523
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 69
- Website
- https://www.bhtherapeutics.com
Valuation
|
Metric
|
BLSM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BLSM
|
|---|---|
Quick Ratio | 5.12 |
Current Ratio | 5.42 |
Interest Coverage | — |
Quick Ratio
BLSM
Profitability
|
Metric
|
BLSM
|
|---|---|
Return on Assets (Normalized) | −55.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
BLSM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$V?&!c | LOCK|N@S% | $127B | |||
| Moderna Inc
MRNA
| LOCK|!d<<N% | LOCK|Q& | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?QlRCq | LOCK|cL#! | $81B | |||
| argenx SE ADR
ARGX
| LOCK|kcmNlf | LOCK|h> | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?%Nb&s> | LOCK|d% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^lWZfbN | LOCK|LP#^% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@%HTl^L | LOCK|$W%# | $27B | |||
| Incyte Corp
INCY
| LOCK|j%^!!Zv | LOCK|$z | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|<J!XM^^ | LOCK|<M< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#p!PFM | LOCK|Wp^ | $14B |
United States